Switzerland vs Türkiye: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Switzerland
92.0%
in 2025
Türkiye
92.0%
in 2025
Switzerland rank
56th
Türkiye rank
56th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Switzerland
- Türkiye
How they compare
Switzerland currently reports 92.0% against 92.0% in Türkiye, a difference of 0.0%.
The two have swapped places 1 time across 18 shared years of data; in 2008 it was Switzerland ahead.
Switzerland ranks 56th and Türkiye ranks 56th of 194 countries.
Türkiye has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Switzerland | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 19.0% | 48.5% | 29.5% | Türkiye |
| 2010s | 71.6% | 96.4% | 24.8% | Türkiye |
| 2020s | 89.2% | 94.5% | 5.3% | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Switzerland or Türkiye?
- Switzerland, at 92.0% against 92.0% in Türkiye as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Switzerland and Türkiye?
- 0.0%, with Switzerland ahead.
- How many years of comparable data are there for Switzerland and Türkiye?
- 18 years are reported by both, from 2008 to 2025.
- How do Switzerland and Türkiye rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Switzerland ranks 56th and Türkiye ranks 56th of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.